Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Journal of Clinical Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck, Tony Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019 · 939 citations

Medicine, Oncology, Pharmacology +17

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

David M. Jackman, William Pao, Gregory J. Riely et al. · Journal of Clinical Oncology · 2009 · 786 citations

Medicine, Oncology, Pharmacology +15

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman et al. · Journal of Thoracic Oncology · 2018 · 592 citations · Full text

Medicine, Oncology, Pharmacology +15

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu et al. · OncoImmunology · 2017 · 445 citations · Full text

Life Sciences, Immunology, Oncology +17